Moderna, Merck breakthrough could usher in wave of cancer vaccines
11 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
🌍 Cross-language spread
This story first appeared in 🇫🇷 French coverage — 7.3 hours before PULSE detected it in English news.
Detected by matching proper nouns and figures that survive translation. Times reflect when each edition's coverage was first indexed.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
"Moderna, Merck breakthrough could usher in wave of cancer vaccines" is generating significant coverage in the Business category, with 17 articles from 11 distinct sources tracked by PULSE so far.
Outlets currently covering the story include Yahoo Finance, USA Today, Reuters and The Globe and Mail. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.
This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.
Generated by PULSE's extractive engine from coverage metadata only — no AI-written claims. Updated 38d ago.
Quick answers
Why is "Moderna, Merck breakthrough could usher in wave of cancer vaccines" trending?
Because 11 independent news sources published 17 articles about it in a short window — a coverage burst PULSE classifies as a trend.
How does PULSE measure this trend?
PULSE scores velocity from the rate of new articles weighted by source diversity, snapshotted hourly. The full method is public on our methodology page.
Is this trend still active?
The status badge on this page updates hourly: rising, peaking, cooling, or archived once coverage stops for 48 hours.
Coverage (22)
- Moderna (MRNA) & Merck (MRK): What’s Happening With These Two Stocks? Yahoo Finance · 38d ago
- Jim Cramer Says Hold on to Moderna (MRNA) After Phase 3 Cancer Trial Yahoo Finance · 38d ago
- Moderna (MRNA), Merck (MRK) Cancer Vaccine Wins in Late-Stage Trial Yahoo Finance · 38d ago
- Do mRNA tumour vaccines herald a new revolution in cancer treatment? The Hindu · 39d ago
- How V940 Works: Mechanism of the Personalized Melanoma Vaccine CancerNetwork · 39d ago
- Will Moderna’s Cancer Vaccine Be Good for People, or Profits? The Nation · 39d ago
- Moderna's personalized cancer vaccine shows promise. Here's why USA Today · 43d ago
- The Merck/Moderna cancer vaccine: How does it work and what are potential barriers to wide use? Reuters · 43d ago
- Stock Market Midday, Aug. 25: Tech Stocks Rebound and Dick's Sporting Goods Plummets 27% The Globe and Mail · 43d ago
- What does Moderna's melanoma treatment mean for cancer research? We asked 2 local experts WBUR · 43d ago
- Moderna’s Cancer Vaccine Gives Stock a New Growth Story. Will It Have a Happy Ending? Barron's · 43d ago
- Cancer Vaccine Breakthrough Lifts 5 Biotech Names. Here’s Who’s Best Positioned. Yahoo Finance · 43d ago
- Moderna Shares Rebound After Pullback Following Cancer Vaccine Rally Yahoo Finance · 43d ago
- Will the new cancer vaccine survive RFK Jr’s America? BBC · 43d ago
- What Moderna Must Do to Take Its Stock to the Next Level Barron's · 43d ago
- Should You Buy Moderna Stock Following Its Cancer Breakthrough? Yahoo Finance · 43d ago
- Moderna Sinks 7% as Traders Book Profits on a 392% Year-to-Date Surge; BioNTech Drops 4%, Merck Slips Yahoo Finance · 43d ago
- Cancer vaccines could transform treatment and prevention – but misinformation about mRNA vaccines threatens their potential CNN · 43d ago
- Wisconsin doctor responds to ‘breakthrough trial’ of new cancer vaccine WPR · 43d ago
- Investors Thought Moderna Was Left for Dead. Then Came a Cancer Breakthrough. WSJ · 46d ago
- A Cancer Vaccine Is Closer Than Ever Bloomberg.com · 46d ago
- Moderna's 177% Surge Powers a Broad Biotech Rally Yahoo Finance · 46d ago
Topics
Related trends
Vaxcyte’s stock jumps as pneumococcal vaccine holds its own against Pfizer's, Merck’s shots
Vaxcyte shares surge following positive late-stage clinical trial results for its pneumococcal vaccine candidate.
Exclusive | She was ready to die. Now she’s in remission
New developments in personalized mRNA cancer vaccines show promise for melanoma and breast cancer, though hurdles in public perception remain.
Merck licenses a KRAS G12D inhibitor for $400M upfront
Merck has entered a multi-billion dollar agreement with China's SciBrunch Therapeutics to develop a preclinical KRAS G12D inhibitor.
Merck, Daiichi pull lung cancer filing after FDA pushback deals another blow to $4B deal
Merck and Daiichi Sankyo pull their US lung cancer drug application following regulatory pushback.
Moderna CEO’s Realistic Approach to Innovation
Moderna shares surge and track toward top September S&P 500 performance as markets eye upcoming clinical data.
Moderna Stock Hits a New High as CEO Says It’s More Than Covid Vaccines
6 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.